Amid the COVID-19 crisis, the global market for Physical Vapor Deposition estimated at US$19.3 Billion in the year 2020, is projected to reach a revised size of US$28.5 Billion by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027.
PVD Equipment, one of the segments analyzed in the report, is projected to record a 5.5% CAGR and reach US$16.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the PVD Materials segment is readjusted to a revised 5.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $5.2 Billion, While China is Forecast to Grow at 9.3% CAGR
The Physical Vapor Deposition market in the U.S. is estimated at US$5.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.2 Billion by the year 2027 trailing a CAGR of 9.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.2% and 4.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.
PVD Services Segment to Record 6.8% CAGR
In the global PVD Services segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2.8 Billion in the year 2020 will reach a projected size of US$4.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.9 Billion by the year 2027, while Latin America will expand at a 7.3% CAGR through the analysis period.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") for violations of 10(b) and 20(a) of the Securities...
YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...
The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in...
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...